|
|
Article: FDA Approves Cozaar to Reduce the Rate of Progression of Nephropathy in Type 2 Diabetic Patients with Nephropathy and Hypertension.
- Article from:
- Business Wire
- Article date:
- September 19, 2002
CopyrightCOPYRIGHT 2002 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health & Pharmaceutical Writers
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Sept. 19, 2002
Cozaar is the Only Medicine to Demonstrate Significant Reduction in
Progression to End-Stage Renal Disease in this Patient Population
The Food and Drug Administration has approved Merck & Co. Inc.'s hypertension drug Cozaar(R) (losartan potassium tablets) to reduce the rate of progression of nephropathy (kidney disease) in type 2 diabetic patients with hypertension and nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio
300 mg/g), the Company announced today.
The new ...